References in periodicals archive ?
For critical care physicians treating severe sepsis, activated protein C offers significant benefit, increasing overall patient survival by approximately 13 percent," said Dr.
CLINICAL TESTING FOR ACTIVATED PROTEIN C RESISTANCE AND FACTOR V LEIDEN
The Clot-Based Tests for Activated Protein C Resistance
The original test for activated protein C resistance that was offered for use in clinical laboratories was a partial thromboplastin time (PTT) performed in the presence and absence of exogenously supplied activated protein C.
The indirect profibrinolytic effects of activated protein C (based on in vitro data [1]) are mediated by the inhibition of plasminogen activator inhibitor-1, which then inhibits endogenous tissue-plasminogen activator.
First, activated protein C inhibits the production of the inflammatory cytokine TNF-[alpha].
Xigris (drotrecogin alfa (activated)) is a recombinant form of human Activated Protein C.
002) in the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial involving 1,690 patients.
Xigris is a recombinant form of human Activated Protein C.
Patients with recurrent thrombosis should, therefore, be tested for resistance to activated protein C to determine its involvement in the disorder.
The frequency of activated protein C resistance has been reported to occur at least tenfold more frequently than deficiencies of protein C, protein S and antithrombin III combined.
Full browser ?